Solution reagent kit

diagnosticfor neutralizing antibodySARS-COV-2

SARS-CoV-2 Neutralizing Antibody ELISA Kit is used for in vitro qualitative/semi—quantitative detec—tion of whether there are neutralizing antibodies against SARS-CoV-2 RBD in the serum, plasma, and whole blood of vaccine vaccinators and recovered patients to assess the body's immune status. This product is suitable for testing by medical institutions at all levels, providing an important supplementary syn- ergy for nucleic acid testing, and better serving the prevention and control of the epidemic. Good specificity and high accuracy High sensitivity, as high as 97%;Good repeatability Easy to operate, 2 hours to complete the detection; High throughput Widely used to help epidemic prevention and control Infection with the SARS-CoV-2 initiates an immune response, which includes the production of antibodies in the blood. The protein-protein inter—action between RBD and ACE2 can be blocked by neutralizing antibodies against SARS-CoV-2 RBD, which provide protection against future infec-tions from viruses. Recombinant human ACE2 receptor protein is used to coat the ELISA microtiter plate, and horseradish peroxidase (HRP) is used to label the new coronavirus (SARS-CoV-2) RBD protein to prepare the enzyme conjugate RBD-HRP to achieve qualitative detection of the level of neutralizing anti- bodies inthe testsample.